A young researcher takes over a refrigerator full of bacteria. Eleven years later, he sells his company for up to 450 million Swiss francs – how is that possible?
Simon Ittig, former ETH researcher, sold his biotech startup after 11 years for up to CHF 450 million. He developed an innovative cancer treatment from bacteria. His success story prompts reflection on entrepreneurship in the Swiss research landscape and how knowledge can be transformed into…
A young researcher takes over a refrigerator full of bacteria. Eleven years later, he sells his company for up to 450 million francs – how is that possible?
Zurich, August 24, 2026 – A remarkable success story has its origins at ETH Zurich: Simon Ittig, a young researcher, founded a biotech company eleven years after taking over a promising, albeit unconventional project, and has now sold it for up to 450 million francs. His approach, based on specific bacteria and their potential to fight cancer, could initiate a paradigm shift in oncology. This development also raises questions about the entrepreneurial spirit in the Swiss research landscape and demonstrates how academic knowledge can be transformed into economic success.
Ittig's journey began when he took over a refrigerator full of modified bacterial strains from a departing colleague. Instead of shelving the project, he recognized the untapped potential of these microorganisms, which are capable of penetrating tumor cells and fighting them from the inside out. From this initial vision, deep research work developed, which eventually led to the founding of his own company. Funding was secured through several rounds, including venture capital from renowned investors who recognized the technology's potential. The sale of the company to a major pharmaceutical group marks not only a personal success for Ittig but also significant recognition for the innovative power of Swiss biotechnology.
The relevance of this story for prospective MBA students and executives lies on several levels. It impressively illustrates the intersection between scientific excellence and entrepreneurial implementation. An MBA program provides exactly those skills needed to develop a viable business model from a promising research idea: from financing strategy and project management to market analysis and leading an interdisciplinary team. Ittig's career shows how crucial business management know-how is to bring technological innovations beyond the laboratory phase into application and to monetize them successfully.
Bridging the Gap Between Research and Business
Ittig's success also raises the question of why more young Swiss researchers do not venture into starting a company. The academic environment in the DACH region is rich in innovation, but the transfer of these innovations into commercially successful ventures could still be optimized. Programs such as an MBA with specializations in Entrepreneurship, Innovation Management, or Life Sciences Business are of decisive importance here. They close the gap between often purely scientific education and market requirements by providing students with the necessary tools to acquire venture capital, manage patents, and bring products to market maturity.